<DOC>
	<DOC>NCT01719692</DOC>
	<brief_summary>A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.</brief_summary>
	<brief_title>Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia</brief_title>
	<detailed_description>Hundreds of Patients without infection (age 18 to 60 years old) developed Chronic ITP. All patients will be enrolled in this study and will be randomly assigned to receive 100 mg rituximab weekly for 4 weeks (group A) or a single dose of 375 mg/m2 rituximab (group B). After treatment all patients will be followed for two years. During observation platelet count and B lymphocyte will be detected every month.</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult chronic ITP, age 18 to 60 pregnant woman with ITP; liver disease and kidney disease; allergy to rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>